Investors hoping for a decisive turnaround at Bayer were met with sobering news as the company released its full-year results. While the German conglomerate met its operational targets for 2025, the guidance for the current year delivered a stark reminder that costly litigation continues to overshadow its business performance, pushing free cash flow deep into negative territory.
A Deepening Deficit Amidst Revenue Growth
The financial statements present a contradictory picture. On an operational level, Bayer managed a slight currency-adjusted increase in sales to approximately 45.6 billion euros, meeting its own forecasts. However, the bottom line tells a different story, heavily marred by legal provisions.
The net loss expanded significantly, growing by over one billion euros year-on-year to nearly 3.6 billion euros. This deterioration is primarily attributed to massive provisions for ongoing U.S. lawsuits, which eclipsed a solid performance from the agricultural division in terms of EBITDA. Consequently, shareholders will once again receive a dividend at the statutory minimum of 0.11 euros per share.
Cash Flow Forecast Sends a Shockwave
The company’s projections for the coming period carry even greater weight. Management anticipates stagnation in both sales and earnings for 2026, but the most alarming guidance concerns liquidity. Bayer expects its free cash flow to plummet to a range of negative 1.5 to negative 2.5 billion euros.
This forecast is driven by anticipated settlement payments totaling around five billion euros. These substantial outlays threaten to reverse recent progress on debt reduction. After successfully lowering net financial debt below the 30 billion euro mark in 2025, it is now projected to climb back to as much as 33 billion euros by the end of this year.
Should investors sell immediately? Or is it worth buying Bayer?
The Persistent Burden of Litigation
The central challenge remains the legal fallout from the Monsanto acquisition. A proposed settlement of roughly 6.8 billion euros to resolve a large portion of the Roundup lawsuits is on the table, but its finalization hinges on approval from U.S. courts. Without judicial clearance and broad acceptance from claimants, the deal could collapse.
Further straining finances are settlements related to the chemical PCB. By the end of 2025, total provisions for all ongoing litigation had already ballooned to 11.8 billion euros.
Market Reaction and Technical Downturn
The disappointing forward outlook triggered an immediate market response. Bayer shares closed yesterday’s (Wednesday) session at 37.80 euros. This price leaves the stock down 0.59 percent for the year-to-date, back in negative territory.
From a chart perspective, conditions have deteriorated. The share price fell decisively below the 50-day moving average of 42.82 euros. The gap to the 52-week high of around 49 euros has now widened to over 23 percent.
Conclusion: A Waiting Game for Investors
For Bayer, 2026 shapes up as a transitional year with an uncertain outcome. As long as negative cash flow erodes the balance sheet and debt levels rise, the company lacks the financial flexibility for major strategic moves. A return to operational focus—and with it, investor confidence—will likely remain on hold until the multi-billion euro settlements receive final legal approval. Until that time, the stock represents a bet on the successful navigation of complex legal challenges by the company’s legal team and its new CFO, Judith Hartmann.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from March 5 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 5.
Bayer: Buy or sell? Read more here...
